Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S Subramaniam

Showing results (381-390 of 387) with videos related to

Pageof 39
Sort By:
You have reached the last page of results.This site can display upto 387 results.
Transboundary and Emerging Diseases|December 6, 2017
Foot-and-mouth disease virus transmission dynamics and persistence in a herd of vaccinated dairy cattle in IndiaS S Hayer, K VanderWaal, R Ranjan, et al.
Lung Cancer (Amsterdam, Netherlands)|March 3, 2018
Randomized phase 2 study of tivantinib plus erlotinib versus single-agent chemotherapy in previously treated KRAS mutant advanced non-small cell lung cancerDavid E Gerber, Mark A Socinski, Joel W Neal, et al.
Journal for Immunotherapy of Cancer|August 8, 2022
Safety, tolerability and efficacy of agonist anti-CD27 antibody (varlilumab) administered in combination with anti-PD-1 (nivolumab) in advanced solid tumorsRachel E Sanborn, Michael J Pishvaian, Margaret K Callahan, et al.
Cell Stem Cell|April 9, 2016
Dclk1 Defines Quiescent Pancreatic Progenitors that Promote Injury-Induced Regeneration and TumorigenesisC Benedikt Westphalen, Yoshihiro Takemoto, Takayuki Tanaka, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 17, 2026
Safety, pharmacokinetics, pharmacodynamics, and preliminary efficacy from a first-in-human study of volrustomig, a novel PD-1/CTLA-4 bispecific antibodyBen Tran, Mark Voskoboynik, Sang-We Kim, et al.
Cancer Discovery|January 9, 2021
Design and Efficacy of a Monovalent Bispecific PD-1/CTLA4 Antibody That Enhances CTLA4 Blockade on PD-1<sup>+</sup> Activated T CellsSimon J Dovedi, Matthew J Elder, Chunning Yang, et al.
Nature Genetics|June 20, 2018
A precision oncology approach to the pharmacological targeting of mechanistic dependencies in neuroendocrine tumorsMariano J Alvarez, Prem S Subramaniam, Laura H Tang, et al.
Pageof 39

Showing results (381-390 of 387) with videos related to

Sort By:
Pageof 39
You have reached the last page of results.This site can display upto 387 results.
Transboundary and Emerging Diseases|December 6, 2017
Foot-and-mouth disease virus transmission dynamics and persistence in a herd of vaccinated dairy cattle in IndiaS S Hayer, K VanderWaal, R Ranjan, et al.
Lung Cancer (Amsterdam, Netherlands)|March 3, 2018
Randomized phase 2 study of tivantinib plus erlotinib versus single-agent chemotherapy in previously treated KRAS mutant advanced non-small cell lung cancerDavid E Gerber, Mark A Socinski, Joel W Neal, et al.
Journal for Immunotherapy of Cancer|August 8, 2022
Safety, tolerability and efficacy of agonist anti-CD27 antibody (varlilumab) administered in combination with anti-PD-1 (nivolumab) in advanced solid tumorsRachel E Sanborn, Michael J Pishvaian, Margaret K Callahan, et al.
Cell Stem Cell|April 9, 2016
Dclk1 Defines Quiescent Pancreatic Progenitors that Promote Injury-Induced Regeneration and TumorigenesisC Benedikt Westphalen, Yoshihiro Takemoto, Takayuki Tanaka, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 17, 2026
Safety, pharmacokinetics, pharmacodynamics, and preliminary efficacy from a first-in-human study of volrustomig, a novel PD-1/CTLA-4 bispecific antibodyBen Tran, Mark Voskoboynik, Sang-We Kim, et al.
Cancer Discovery|January 9, 2021
Design and Efficacy of a Monovalent Bispecific PD-1/CTLA4 Antibody That Enhances CTLA4 Blockade on PD-1<sup>+</sup> Activated T CellsSimon J Dovedi, Matthew J Elder, Chunning Yang, et al.
Nature Genetics|June 20, 2018
A precision oncology approach to the pharmacological targeting of mechanistic dependencies in neuroendocrine tumorsMariano J Alvarez, Prem S Subramaniam, Laura H Tang, et al.
Pageof 39